Second quarter revenue increased 14% year-over-year to $45.5 millionCommercial Cell & Gene Therapy revenue increased 33% year ...

Abeona has also received FDA approval for ZEVASKYN, a cell-based gene therapy for recessive dystrophic epidermolysis bullosa, with the first patient treatments expected in the third quarter of 2025.

- ZEVASKYN is the only FDA-approved therapy to treat RDEB wounds with a single application - CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced ...

CLEVELAND, July 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of the newest Qualified Treatment Center (QTC) for FDA-approved ZEVASKYN ...

- Abeona Therapeutics ® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration (FDA) approval of ZEVASKYN in April 2025 ...